Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of FibroGen Inc (NASDAQ: FGEN) was $0.34 for the day, up 0.81% from the previous closing price of $0.33. In other words, the price has increased by $0.81 from its previous closing price. On the day, 0.97 million shares were traded. FGEN stock price reached its highest trading level at $0.3526 during the session, while it also had its lowest trading level at $0.33.
Ratios:
Our analysis of FGEN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on August 08, 2023, Downgraded its rating to Underperform and sets its target price to $2 from $4 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 12 ’24 when Adib Deyaa bought 22,123 shares for $1.17 per share. The transaction valued at 25,884 led to the insider holds 82,123 shares of the business.
Wettig Thane bought 50,000 shares of FGEN for $95,470 on Mar 07 ’24. The CEO now owns 470,178 shares after completing the transaction at $1.91 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FGEN now has a Market Capitalization of 33999796 and an Enterprise Value of 103849944. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.17. Its current Enterprise Value per Revenue stands at 0.597 whereas that against EBITDA is -0.626.
Stock Price History:
The Beta on a monthly basis for FGEN is 0.73, which has changed by -0.3149284 over the last 52 weeks, in comparison to a change of 0.2936039 over the same period for the S&P500. Over the past 52 weeks, FGEN has reached a high of $2.93, while it has fallen to a 52-week low of $0.18. The 50-Day Moving Average of the stock is -7.13%, while the 200-Day Moving Average is calculated to be -67.71%.
Shares Statistics:
FGEN traded an average of 1.23M shares per day over the past three months and 1749490 shares per day over the past ten days. A total of 98.77M shares are outstanding, with a floating share count of 93.78M. Insiders hold about 6.94% of the company’s shares, while institutions hold 45.77% stake in the company. Shares short for FGEN as of 1730332800 were 4324077 with a Short Ratio of 3.52, compared to 1727654400 on 4544637. Therefore, it implies a Short% of Shares Outstanding of 4324077 and a Short% of Float of 5.07.
Earnings Estimates
The market rating of FibroGen Inc (FGEN) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.86 and -$0.86 for the fiscal current year, implying an average EPS of -$0.86. EPS for the following year is -$0.38, with 1.0 analysts recommending between -$0.38 and -$0.38.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 1 analysts. It ranges from a high estimate of $24M to a low estimate of $24M. As of the current estimate, FibroGen Inc’s year-ago sales were $27.14MFor the next quarter, 1 analysts are estimating revenue of $39.43M. There is a high estimate of $39.43M for the next quarter, whereas the lowest estimate is $39.43M.
A total of 2 analysts have provided revenue estimates for FGEN’s current fiscal year. The highest revenue estimate was $177M, while the lowest revenue estimate was $169.33M, resulting in an average revenue estimate of $173.16M. In the same quarter a year ago, actual revenue was $147.75MBased on 2 analysts’ estimates, the company’s revenue will be $152.32M in the next fiscal year. The high estimate is $159.64M and the low estimate is $145M.
